Dr. Reddy’s Laboratories Ltd., in collaboration with Shanghai Junshi Biosciences Co. Ltd., today announced the launch of Toripalimab under the brand name Zytorvi® in India. Toripalimab is a next-generation PD-1 inhibitor and the first immuno-oncology therapy approved by global regulatory authorities such as the USFDA, EMA, MHRA, and DCGI for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).

India is now the third country in the world, after the United States and China, to gain access to this revolutionary treatment in the same year as its U.S. launch.

Superior Outcomes for a Rare Cancer

Toripalimab is indicated as a first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with standard chemotherapy (gemcitabine and cisplatin), demonstrating a 48% reduction in risk of progression or death compared to chemotherapy alone. It is also approved as monotherapy for patients with recurrent or metastatic NPC who have progressed on or after platinum-based chemotherapy.

A Milestone for Oncology in India

Dr. M.V. Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, highlighted the significance of this launch:

"The launch of Toripalimab is a significant milestone for patients diagnosed with nasopharyngeal carcinoma (NPC) in India. As the next-generation PD-1 inhibitor, Toripalimab meets an urgent unmet need for this rare and challenging disease, offering improved outcomes for patients in advanced stages."

India is among the top five countries globally in terms of NPC disease burden, with over 6,500 new cases reported in 2022, according to GLOBOCAN. The north-eastern states, particularly Nagaland, report the highest incidence rates of this rare cancer.

Comprehensive Oncology Ecosystem

Dr. Reddy’s has strategically positioned oncology as a core focus area with a robust portfolio of small molecules, biosimilars, and novel biologics. The addition of Zytorvi® builds on the company's goal to provide access to innovation and establish an end-to-end ecosystem of care for patients in India and emerging markets.

About Toripalimab

Toripalimab is a monoclonal antibody that inhibits PD-1 interactions with PD-L1 and PD-L2, promoting the immune system’s ability to identify and destroy cancer cells. This mechanism enhances receptor internalization and strengthens anti-tumor activity.

Commitment to Innovation and Access

Through its license and commercialization agreement with Shanghai Junshi Biosciences, Dr. Reddy’s has obtained exclusive rights to develop and commercialize Toripalimab in 21 countries, including India, South Africa, and Latin America, with potential expansion into Australia and New Zealand.